ASND Financials

Income Statement
MetricQ2 2019Q1 2019Q4 2018Q3 2018Q2 2018
Revenue
157.0K
1.5M
-96.4%
40.8M
+351.3%
9.0M
Cost of Revenue
0
0
0
0
0
Gross Profit
157.0K
1.5M
-96.4%
40.8M
+351.3%
9.0M
Operating Expenses
35.7M
+5.5%
33.8M
+0.6%
33.6M
-0.6%
33.8M
-10.9%
37.9M
R&D
25.5M
+15.9%
22.0M
-3.3%
22.8M
-3.0%
23.5M
-11.8%
26.6M
SG&A
10.1M
-13.8%
11.8M
+8.8%
10.8M
+5.1%
10.3M
-8.9%
11.3M
Operating Income
-35502000
-5.1%
-33792000
-5.3%
-32106000
-557.5%
7.0M
+124.3%
-28877000
EBITDA
-33522000
-5.4%
-31797000
+1.0%
-32106000
-459.7%
8.9M
+133.1%
-26957000
Net Income
-41087000
-49.9%
-27412000
+24.2%
-36173000
-790.1%
5.2M
+112.0%
-43845000
EPS (Basic)
$-0.07
-75.0%
$-0.04
+33.3%
$-0.06
-700.0%
$0.01
+112.5%
$-0.08
EPS (Diluted)
$-0.07
-75.0%
$-0.04
+33.3%
$-0.06
-700.0%
$0.01
+112.5%
$-0.08
Shares (Diluted)
629.4M
+0.2%
627.9M
+7.5%
584.3M
-6.0%
621.8M
+10.0%
565.2M
Ascendis Pharma A/S Ordinary Share (ASND) — Financials